Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR
SG Wu, CH Gow, YL Chen, YN Liu… - … Journal of Cancer, 2023 - Wiley Online Library
Abstract EGFR exon 19 deletion (Del‐19) comprises multiple advanced NSCLC subtypes.
EGFR‐tyrosine kinase inhibitor (TKI) efficacy and T790M acquisition in various Del‐19 …
EGFR‐tyrosine kinase inhibitor (TKI) efficacy and T790M acquisition in various Del‐19 …
[HTML][HTML] Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients
J Su, W Zhong, X Zhang, Y Huang, H Yan, J Yang… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Patients with non-small cell lung cancer (NSCLC) with activating epidermal growth factor
receptor (EGFR) mutations (exon 19 deletions and L858R) benefit from EGFR tyrosine …
receptor (EGFR) mutations (exon 19 deletions and L858R) benefit from EGFR tyrosine …
[HTML][HTML] Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition …
Y Wang, R Zheng, P Hu, Z Zhang, S Shen, X Li - BMC cancer, 2021 - Springer
Background In the existing next generation sequencing (NGS) system, epidermal growth
factor receptor (EGFR) exon 19 deletion-insertion (19delins) is still interpreted into the …
factor receptor (EGFR) exon 19 deletion-insertion (19delins) is still interpreted into the …
Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first‐line tyrosine kinase inhibitors: A single‐center …
Y Gu, J Yu, H Hu, H Zhang, B Cao, L Liang - Thoracic Cancer, 2023 - Wiley Online Library
Background Clinical significance of various subtypes of epidermal growth factor receptor
(EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) …
(EGFR) exon 19 deletion (ex19del) mutation in non‐small cell lung cancer (NSCLC) …
Concomitant mutations in EGFR 19Del/L858R mutation and their association with response to EGFR-TKIs in NSCLC patients
H Liang, C Li, Y Zhao, S Zhao, J Huang… - Cancer Management …, 2020 - Taylor & Francis
Objective Differences in efficacy of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKI) have been observed between non-small cell lung cancer (NSCLC) …
inhibitors (EGFR-TKI) have been observed between non-small cell lung cancer (NSCLC) …
Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer
T Kaneda, A Hata, H Tomioka, K Tanaka, R Kaji… - Lung Cancer, 2014 - Elsevier
Abstract Background Exon 19 deletion mutations (Del-19s) and the exon 21 L858R point
mutation are the most common epidermal growth factor receptor (EGFR) mutations. In Del …
mutation are the most common epidermal growth factor receptor (EGFR) mutations. In Del …
Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs
Y Tang, N Che, Y Yu, Y Gao, H Shi, Q Feng… - Journal of Cancer …, 2020 - Springer
Introduction Next-generation sequencing (NGS)-based assays to understand various
mutations and co-occurrence of genomic alterations in non-small cell lung cancer (NSCLC) …
mutations and co-occurrence of genomic alterations in non-small cell lung cancer (NSCLC) …
Exon 19 deletion association with progression-free survival compared to L858R mutation at exon 21 in treatment with first-line EGFR-TKIs: A meta-analysis of …
W Liang, J Sheng, X Wu, Y Zhang, S Kang, L Zhang - 2014 - ascopubs.org
8107 Background: The superior efficacy of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs) compared with cytotoxic chemotherapy in patients harboring …
inhibitors (EGFR-TKIs) compared with cytotoxic chemotherapy in patients harboring …
Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
9098 Background: There is currently no targeted therapy approved for patients with EGFR
exon 20 insertion mutations (exon20ins) in NSCLC. Real world treatment outcome evidence …
exon 20 insertion mutations (exon20ins) in NSCLC. Real world treatment outcome evidence …
Comprehensive genomic profiling identifies frequent drug-sensitive EGFR exon 19 deletions in NSCLC not identified by prior molecular testing
AB Schrock, GM Frampton, D Herndon… - Clinical Cancer …, 2016 - AACR
Purpose: Reliable detection of drug-sensitive activating EGFR mutations is critical in the
care of advanced non–small cell lung cancer (NSCLC), but such testing is commonly …
care of advanced non–small cell lung cancer (NSCLC), but such testing is commonly …
相关搜索
- egfr exon nsclc patients
- deletion subtypes nsclc patients
- egfr exon deletion subtypes
- clinical outcomes nsclc patients
- molecular characteristics nsclc patients
- egfr tkis t790m acquisition
- t790m acquisition treatment efficacies
- egfr tkis treatment efficacies
- t790m acquisition nsclc patients
- treatment efficacies nsclc patients
- egfr tkis clinical outcomes
- egfr tkis concomitant mutations
- concomitant mutations nsclc patients
- egfr tkis molecular characteristics
- egfr tkis nsclc patients
- insertion mutations nsclc patients